Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Dec 31;19(4):392-396.
doi: 10.18502/jovr.v19i4.17786. eCollection 2024 Dec.

New Sight for Old: Commentary On the Use of Pilocarpine for Presbyopia

Cameron F Parsa  1   2
Affiliations
Editorial

New Sight for Old: Commentary On the Use of Pilocarpine for Presbyopia

Cameron F Parsa. J Ophthalmic Vis Res. .
No abstract available

PubMed Disclaimer

References

    1. Benozzi G, Cortina ME, Gimeno E, Vantesone DL, Solas AE, Lorda GM, et al. A multicentric study of pharmacological treatment for presbyopia. Graefes Arch Clin Exp Ophthalmol 2021;259:2441–2450. - PubMed
    1. Montés-Micó R, Charman WN. Pharmacological strategies for presbyopia correction. J Refract Surg 2019;35:803–814. - PubMed
    1. Waring GO 4 th, Price FW Jr, Wirta D, McCabe C, Moshirfar M, Guo Q, et al. Safety and efficacy of AGN-190584 in individuals with presbyopia: The GEMINI 1 Phase 3 randomized clinical trial. JAMA Ophthalmol 2022;140:363–371. - PMC - PubMed
    1. ClinicalTrials.gov. A phase 3 efficacy study of pilocarpine HCl ophthalmic solution (AGN-190584) in participants with presbyopia (GEMINI 2). https://clinicaltrials.gov/study/ NCT03857542?cond=NCT03857542&rank=1
    1. Kannarr S, El-Harazi SM, Moshirfar M, Lievens C, Kim JL, Peace JH, et al. Safety and efficacy of twice-daily Pilocarpine HCl in presbyopia: The Virgo Phase 3, randomized, double-masked, controlled study. Am J Ophthalmol 2023;253:189–200. - PubMed

Publication types

LinkOut - more resources